We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Hutchison China MediTech

FY18 results as expected, plentiful news flow in FY19

Lighthouse | 11 March 2019

e-therapeutics

Setting the stage

Update | 06 March 2019

BerGenBio

Resolution of Rigel arbitration reduces uncertainty

Lighthouse | 01 March 2019

Bonesupport

Gearing up for growth

Update | 01 March 2019

Hutchison China MediTech

ASCO GU: promising PRCC data for savo/durva combo

Update | 20 February 2019

BerGenBio

Axl ready to turn another revolution

Outlook | 14 February 2019

MaxCyte

Capital raised to advance CARMA primarily

Lighthouse | 06 February 2019

Hutchison China MediTech

Global aspirations for a top-class Chinese innovator

Initiation | 06 February 2019

Tissue Regenix Group

New strategy delivering results

Update | 04 February 2019

Scancell

Interim results show progress being maintained

Update | 31 January 2019
1 2 3 4 5 6 7 8 9 10 11
110 results found.